X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Bristol includes RYZ101 (actinium-225 dotatate) targeting somatostatin receptor 2. It is currently being evaluated in patients for the treatment of SSTR-positive Gastroenteropancreatic Neuroendocrine Tumors.
Lead Product(s): Actinium-225 Dotatate
Therapeutic Area: Oncology Product Name: RYZ101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $4.1 million Upfront Cash: $4.1 million
Deal Type: Acquisition February 26, 2024
Details:
By acquiring RayzeBio’s differentiated actinium-based radiopharmaceutical platform, BMS will establish its presence in one of the most promising and fastest-growing new modalities for solid tumors, by delivering radioactive payloads to cancer cells in a targeted manner.
Lead Product(s): Actinium-225 Dotatate
Therapeutic Area: Oncology Product Name: RYZ101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $4,100.0 million Upfront Cash: $4,100.0 million
Deal Type: Acquisition December 26, 2023
Details:
RYZ101 (Actinium-225 DOTATATE) is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), in patients with SSTR+ gastroenteropancreatic neuroendocrine tumors.
Lead Product(s): Actinium-225 Dotatate
Therapeutic Area: Oncology Product Name: RYZ101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
The proceeds will advance clinical development of RYZ101 (actinium-225 dotatate) in company's Phase 3 trial in GEP-NETs, RYZ101 through Phase 1b efficacy data in ES-SCLC and IND enabling activities and clinical development of RYZ801 and RYZ811 in HCC through Phase 1.
Lead Product(s): Actinium-225 Dotatate
Therapeutic Area: Oncology Product Name: RYZ101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $358.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 19, 2023
Details:
The proceeds will advance IND enabling activities and clinical development of RYZ801, a novel proprietary peptide which targets GPC3 for delivery of Ac225, and RYZ811 in HCC through Phase 1b safety data and the development of RYZ101 for GEP-NETs and extensive-stage SCLC.
Lead Product(s): RYZ801,Actinium-225
Therapeutic Area: Oncology Product Name: RYZ801
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering August 25, 2023
Details:
RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), in patients with SSTR+ gastroenteropancreatic neuroendocrine tumors.
Lead Product(s): Actinium-225 Dotatate
Therapeutic Area: Oncology Product Name: RYZ101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
Novel peptide drug candidate against GPC3 was nominated as GPC3 is selectively overexpressed in hepatocellular carcinoma and not expressed in normal liver and other tissues, making it the potential targeted cancer therapy.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing SSTR2.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Product Name: RYZ101
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing the somatostatin receptor type 2 (SSTR2).
Lead Product(s): RYZ101
Therapeutic Area: Oncology Product Name: RYZ101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing the somatostatin receptor type 2 (SSTR2).
Lead Product(s): RYZ101
Therapeutic Area: Oncology Product Name: RYZ101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Viking Global Investors
Deal Size: $160.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing September 13, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
